02:20 PM EDT, 05/23/2025 (MT Newswires) -- Bicara Therapeutics ( BCAX ) shares fell 44% in recent trading Friday, a day after the company said that its latest clinical trial for a potential head and neck cancer treatment has yet to reach median overall survival.

The Phase 1/1b trial evaluates ficerafusp alfa in combination with pembrolizumab in patients with first line recurrent/metastatic head and neck squamous cell carcinoma, the company said.

Intraday volume topped 5.49 million shares versus the daily average of about 588,000.

Price: 8.70, Change: -6.96, Percent Change: -44.46